Monitoring of endothelial cell activation in experimental sepsis with a two-step cell culture model

Abstract

The aim of this work was to establish and characterize a cell culture model for lipopolysaccharide (LPS)-induced activation of human endothelial cells. Monocytic THP-1 cells were stimulated for 4 h with 10 ng/ml LPS from Pseudomonas aeruginosa in media containing 10% human plasma. Culture supernatants containing LPS and factors secreted by THP-1 in response to stimulation were applied to human umbilical vein endothelial cells (HUVECs). Nuclear factor-κB (NF-κB) activity, expression of adhesion molecules, and cytokine secretion were quantified. In addition, the effect of adsorptive removal of tumour necrosis factor-α (TNF-α) from the THP-1 culture supernatant on HUVEC activation was assessed. After 4 h of stimulation, THP-1 cells secreted various mediators including TNF-α (854 ± 472 pg/ml), interleukin (IL)-8 (2069 ± 710 pg/ml), IL-18 (305 ± 124 pg/ml), IL-10 (14 ± 5 pg/ml), and IL-1β (24 ± 11 pg/ml). Stimulated HUVECs showed significantly increased NF-κB activity and secreted high amounts of IL-6 and IL-8. Additionally, adhesion molecules ICAM-1 and E-selectin were increased both in the culture supernatant and at the cell surface. Removal of TNF-α from the THP-1 culture supernatant prior to HUVEC stimulation resulted in a decrease in NF-κB activity, expression of adhesion molecules, as well as IL-6 secretion. The cell culture model established in this study permits the monitoring of LPS-induced endothelial activation, which plays a central role in sepsis and may serve to assess the effect of mediator modulation by methods such as extracorporeal blood purification.

Keywords

cytokines blood purification endothelial dysfunction inflammation lipopolysaccharide

References

Levy MM , Fink MP , Marshall JC et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med 2003; 29: 530-538.

Angus DC , Linde-Zwirble WD , Lidicker J. , Clermont G. , Carcillo J. , Pinsky MR Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.

Martin GS , Mannino DM , Eaton S. , Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554.

O’Brien JM , Ali NA , Aberegg SK , Abraham E. Sepsis. Am J Med 2007; 120: 1012-1022.

Medhzitov R. , Janeway C. Innate immune recognition: mechanisms and pathways. Immunol Rev 2000; 173: 89-97.

Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007; 449: 819-826.

Cohen J. The immunopathogenesis of sepsis. Nature 2002 ; 420: 885-891.

Annane D. , Bellisant E. , Cavaillon JM Septic shock. Lancet 2005; 365: 63-78.

Markiewski MM , Nilsson B. , Ekdahl KN , Mollnes TE , Lambris JD

Complement and coagulation: strangers or partners in crime?

Trends Immunol 2007; 28: 184-192.

10.

Ward P. The dark side of C5a in sepsis. Nat Rev Immunol 2004; 4: 133-142.

11.

Lehr HA , Bittinger F. , Kirkpatrick CJ

Microcirculatory dysfunction in sepsis: a pathogenic basis for therapy?

J Pathol 2000; 190: 373-386.

12.

Aird WC The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003; 101: 3765-3777.

13.

Ploder M. , Pelinka L. , Schmuckenschlager C. et al. Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock 2006; 25: 129-134.

14.

Hotchkiss RS , Nicholson DW Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006 ; 6: 813-822.

15.

Marshall JC Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2003 ; 2: 391-405.

16.

Riedemann NC , Guo RF , Ward PA Novel strategies for the treatment of sepsis . Nat Med 2003; 5: 517-524.

17.

Bernard GR , Vincent JL , Laterre PF et al. Efficacy and safety of recombinant activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.

18.

Bellomo R. , Honoré P. , Matson J. , Ronco C. , Winchester J. Extracorporeal blood treatment methods in SIRS/sepsis. Int J Artif Organs 2005; 28: 450-458.

19.

Jaber BL , Pereira PJG. Extracorporeal adsorbent-based strategies in sepsis. Am J Kidney Dis 1997; 30: S44-S56.

20.

Falkenhagen D. , Schima H. , Loth F. Arrangement for removing substances from liquids, in particular blood. Patent WO9504559; Japanese Patent #50 1083 (1997); US Patent #5,855,782 ( 1999).

21.

Ronco C. The immunomodulatory effect of extracorporeal therapies in sepsis: a reconciliation of three theories. Int J Artif Organs 2007 ; 30: 855-857.

22.

Schefold JC , von Haehling S. , Corsepius M. et al. A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product C5a. Shock 2007; 28: 418-425.

23.

Rittirsch D. , Flierl MA , Ward PA Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8: 776-787.

24.

Magder S. , Neculcea J. , Neculcea V. , Sladek R. Lipopolysaccharide and TNF-α produce very similar changes in gene expression in human endothelial cells. J Vasc Res 2006 ; 43: 447-461.

25.

López-Bojórquez LN , Arechavaleta-Velasco F. , Vadillo-Ortega F. , Móntes-Sánchez D. , Ventura-Gallegos JL , Zentella-Dehesa A. NF-κB translocation and endothelial cell activation is potentiated by macrophage-released signals co-secreted with TNF-α and IL-1β. Inflamm Res 2004; 53: 567-575.

26.

Zhao B. , Bowden RA , Stavchansky SA , Bowman PD Human endothelial cell response to Gram-negative lipopolysaccharide assessed with cDNA microarrays. Am J Physiol 2001; 281: C1587-C1595.

27.

Sharif O. , Boshakov VN , Raines S. , Newham P. , Perkins ND Transcriptional profiling of the LPS induced NF-κB response in macrophages . BMC Immunol 2007; 8: 1.

28.

Hein OV , Misterek K. , Tessmann J-P. , van Dossow V. , Krimphove M. , Spies C. Time course of endothelial damage in septic shock: prediction of outcome . Crit Care 2005; 9: R323-R330.